Navigation Links
Arimidex Beats Tamoxifen in Keeping Breast Cancer at Bay
Date:12/14/2007

After more than 8 years of follow-up, older women taking the newer drug fared better, study finds

FRIDAY, Dec. 14 (HealthDay News) -- The aromatase inhibitor drug Arimidex continues to outpace the old standard tamoxifen when it comes to preventing recurrences of hormone-receptor-positive breast cancers in postmenopausal women.

Even three years after treatment was stopped, women taking Arimidex still saw a benefit, researchers said.

"It has been very good news," said Dr. Aman Buzdar, U.S. principal investigator of the ATAC (Arimidex or Tamoxifen Alone or in Combination) trial, the results of which were expected to be presented Friday at the 2007 San Antonio Breast Cancer Symposium.

"A lot more women receiving Arimidex are free of cancer compared to tamoxifen, and the 100-month data show that these differences, if anything, with time actually continued to increase -- meaning there were fewer and fewer recurrences on Arimidex compared with tamoxifen," Buzdar said.

"Arimidex is the standard of care for postmenopausal women with receptor-positive breast cancer," confirmed Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La. "One hundred months [over eight years] of follow-up is very profound. It's a true credit to the investigators to be able to do the study and have that much follow-up, and it shows that we have reached a new level of care for postmenopausal women. That's what I use and continue to use."

Hormone-receptor-positive cancers respond to circulating estrogen or progesterone. Experts estimate that from 50 percent to 70 percent of breast cancers are hormone receptor positive.

The new findings were also expected to be published in the journal The Lancet Oncology to coincide with the presentation.

Arimidex (anastrozole) is an aromatase inhibitor, a relatively new class of compounds that blocks estrogen production in the body. According to Buzdar, who is professor of medicine and deputy chair of the department of breast medical oncology at the University of Texas M.D. Anderson Cancer Center, Arimidex is now indicated for postmenopausal women who have a hormone-dependent cancer.

Tamoxifen, which has been the gold standard of care in breast cancer treatment for more than 20 years, hinders the tumor's ability to use estrogen. Because Arimidex does not interfere with ovarian function, tamoxifen should still be used by premenopausal women with active ovaries, Buzdar said.

The first major results from ATAC, reported in 2001, found that Arimidex was more effective than tamoxifen in preventing a breast cancer recurrence and was better tolerated.

Subsequent data continued to show positive results.

The current data represent five years of active treatment plus three additional years of follow-up. In all, more than 9,000 women in 21 countries were involved in the study.

All the women had early-stage disease and had undergone surgery with or without chemotherapy and/or radiation. Eighty-four percent of participants had hormone-receptor-positive tumors.

The women were randomized to receive Arimidex alone or tamoxifen alone (a third arm involving a combination therapy had been halted earlier).

At the time of this 100-month follow-up, the mean age of participants was 72 years.

Arimidex improved disease-free survival by 15 percent compared with tamoxifen in women with hormone-receptor-positive breast cancer. The drug reduced the risk of all recurrences by 24 percent.

The improvement persisted even after treatment was stopped.

"The other question which was in all of our minds was what happens after you stop the pill," Buzdar said. "The pill was stopped three years ago, and the effect continues to be there. Even after stopping therapy, there are fewer recurrences in people who took Arimidex in the past."

The most common side effects were joint pain and estrogen deprivation leading to osteoporosis. Once the pill was stopped, however, a woman's risk of developing osteoporosis returned to normal. No new side effects were seen.

"Not only are you keeping more patients alive free of disease, but the safety profile is much more predictable and much more favorable than tamoxifen," Buzdar said.

More information

There's more on aromatase inhibitors at the U.S. National Cancer Institute.



SOURCES: Aman Buzdar, M.D., professor, medicine and deputy chair, department of breast medical oncology, University of Texas M.D. Anderson Cancer Center, Houston; Jay Brooks, M.D., chairman, hematology/oncology, Ochsner Health System, Baton Rouge, La.; Dec. 14, 2007, presentation, 2007 San Antonio Breast Cancer Symposium


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA
2. Study: HPV test beats Pap in detecting cervical cancer
3. Ultrasound Beats Blood Test for Gauging Ovarian Cancers: Study
4. Honey Beats Meds at Soothing Kids Cough
5. Tamoxifen Helps Treat Bipolar Disorder
6. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
7. FORGET THE JONESES, This is All About Keeping up With the Walkers as the Los Angeles Jewish Home Sends Out an Invite to Everyone Named Walker in the United States
8. Statins reduce loss of function, keeping old lungs young - even in smokers
9. Random drug testing not reliable in keeping teen athletes from using
10. Tips for Keeping Food Portions Under Control, from Harvard Womens Health Watch
11. Is fear of gaining weight keeping many women from trying to quit smoking?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Arimidex Beats Tamoxifen in Keeping Breast Cancer at Bay
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite ... program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the ...
(Date:10/12/2017)... ... , ... In the United States, single-family home owners pay ... York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is $7,000 a ... rates, which contributes to the relatively lower cost of living in places like ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the University of California Berkeley, and other leading institutions in announcing the launch ... of institutions to change the way animals are raised for food. , Founding ...
(Date:10/12/2017)... San Antonio, Texas (PRWEB) , ... October 12, ... ... medical device and biologics manufacturer, has expanded its executive staff with the addition ... Development. , In this role, Slott will develop the national distribution and sales ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading ... announced that its MyDario product is expected to appear on The Dr. ... The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show ... The segment ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology: